Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis

Background Focal inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) diminishes with increasing age. Here we use patient-level data from randomised controlled trials (RCTs) of natalizumab treatment in RRMS to investigate the association of age and inflammatory disease activity. Methods We used patient-level data from the AFFIRM (natalizumab vs placebo in…

Read the full article here

Source: Journal of Neurology, Neurosurgery & Psychiatry

Categories: Latest Headlines, Neurology

Tweets with this article

Nat Rev Neurology

"Patient age should be taken into consideration when deciding on immunomodulatory treatment in RRMS" https://t.co/iTMClW2Cnr

Related Articles

The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology

Nature Reviews Neurology – In this Perspective, the authors propose a new classification system for amyotrophic lateral sclerosis and related neurodegenerative disorders that recognizes, in…

Nat Rev Neurology May 20, 2024

IDH inhibition in gliomas: from preclinical models to clinical trials

Nature Reviews Neurology – Gliomas are the most common malignant primary brain tumours in adults, and they frequently contain mutations in the isocitrate dehydrogenase 1…

Nat Rev Neurology May 17, 2024

Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms

Nature Reviews Neurology – Nociplastic pain arises from altered nociception despite the absence of tissue damage. In this Review, the authors summarize the risk factors…

Nat Rev Neurology May 16, 2024

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results

Nature Medicine – Interim results from the low-dose cohort of the PROCLAIM trial show that AAV-based delivery of the progranulin gene in patients with frontotemporal…

Nat Rev Neurology May 14, 2024

CAR T cells offer hope in glioblastoma

Nature Reviews Neurology – Novel CAR T cells delivered directly to the CNS could have therapeutic effects in recurrent glioblastoma, according to two early-stage trials.

Nat Rev Neurology May 14, 2024

Blood test for early Parkinson disease diagnosis

Nature Reviews Neurology – Blood test for early Parkinson disease diagnosis

Nat Rev Neurology May 14, 2024

Genetic protection against Alzheimer disease

Nature Reviews Neurology – Genetic protection against Alzheimer disease

Nat Rev Neurology May 14, 2024

Infant microbiome predicts neurodevelopmental disorders

Nature Reviews Neurology – Infant microbiome predicts neurodevelopmental disorders

Nat Rev Neurology May 14, 2024

Nanoprobe for blood–brain barrier changes

Nature Reviews Neurology – Nanoprobe for blood–brain barrier changes

Nat Rev Neurology May 14, 2024

Artificial intelligence in epilepsy — applications and pathways to the clinic

Nature Reviews Neurology – Integration of artificial intelligence into epilepsy management could revolutionize diagnosis and treatment. In this Review, the authors provide an overview of…

Nat Rev Neurology May 9, 2024